In vitro and in vivo evaluation of electrochemotherapy with trans-platinum analogue trans-[PtCl2(3-Hmpy)2]

Radiology and Oncology

Simona Kranjc¹  Janez Scancar²  Sabina Grabner³  Gregor Sersa⁴  Maja Cemazar⁵ 

[1] Corresponding authorInstitute of Oncology Ljubljana, Department of Experimental Oncology, Ljubljana, Slovenia;Department of Environmental Sciences, Jozef Stefan Institute, Ljubljana, SloveniaOther articles by this author:;Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, SloveniaOther articles by this author:;Institute of Oncology Ljubljana, Department of Experimental Oncology, Ljubljana, SloveniaFaculty of Health Sciences, University of Ljubljana, Ljubljana, SloveniaOther articles by this author:;Institute of Oncology Ljubljana, Department of Experimental Oncology, Ljubljana, SloveniaUniversity of Primorska, Faculty of Health Sciences, Izola, SloveniaOther articles by this author:

关键词: platinum analogue;    cisplatin;    3-Hmpy;    electroporation;    electrochemotherapy;    mouse sarcoma;   

DOI  :  10.1515/raon-2017-0034

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundCisplatin is used in cancer therapy, but its side effects and acquired resistance to cisplatin have led to the synthesis and evaluation of new platinum compounds. Recently, the synthesized platinum compound trans-[PtCl2(3-Hmpy)2] (3-Hmpy = 3-hydroxymethylpyridine) (compound 2) showed a considerable cytotoxic and antitumour effectiveness. To improve compound 2 cytotoxicity in vitro and antitumour effectiveness in vivo, electroporation was used as drug delivery approach to increase membrane permeability (electrochemotherapy).

【 授权许可】

Unknown